Quidel Corporation Asset Resilience Ratio

Latest as of December 2025: 0.56%

Quidel Corporation asset resilience ratio. Quidel Corporation (QDEL) has an Asset Resilience Ratio of 0.56% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Quidel Corporation to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$32.40 Million
Cash + Short-term Investments

Total Assets

$5.77 Billion
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Quidel Corporation (2009–2025)

Asset resilience ratio of Quidel Corporation from 2009 to 2025. This chart shows how Quidel Corporation's Asset Resilience Ratio has changed over time. Read debt load of Quidel Corporation for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Quidel Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Quidel Corporation (QDEL) total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $32.40 Million 0.56%
Total Liquid Assets $32.40 Million 0.56%

Asset Resilience Insights

  • Limited Liquidity: Quidel Corporation maintains only 0.56% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Quidel Corporation Industry Peers by Asset Resilience Ratio

Compare Quidel Corporation's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Double Medical Technology Inc
SHE:002901
Medical Devices 12.59%
BMC Medical Co. Ltd. A
SHE:301367
Medical Devices 44.96%
Emvision Medical Devices Ltd
AU:EMV
Medical Devices 0.06%
Hironic Co. Ltd
KQ:149980
Medical Devices 17.42%
DRGEM Corporation
KQ:263690
Medical Devices 2.12%
Oncosil Medical Ltd
AU:OSL
Medical Devices 0.00%
Adherium Ltd
AU:ADR
Medical Devices 15.45%

Quidel Corporation Asset Resilience Ratio by Year (2009–2025)

Quidel Corporation asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for Quidel Corporation.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.56% $32.40 Million $5.77 Billion -0.19pp
2024-12-31 0.75% $48.40 Million $6.42 Billion +0.19pp
2023-12-31 0.57% $48.40 Million $8.56 Billion -0.02pp
2022-12-31 0.59% $52.10 Million $8.86 Billion -0.47pp
2021-12-31 1.06% $25.70 Million $2.43 Billion --
2020-12-31 0.00% $0.00 $1.87 Billion --
2017-12-31 0.00% $0.00 $935.25 Million --
2016-12-31 0.00% $0.00 $388.25 Million --
2015-12-31 0.02% $63.00K $406.50 Million -0.68pp
2014-12-31 0.70% $3.13 Million $447.41 Million +0.34pp
2013-12-31 0.36% $969.00K $271.49 Million --
2012-12-31 0.00% $0.00 $242.10 Million --
2011-12-31 0.00% $0.00 $278.89 Million --
2009-12-31 2.40% $4.00 Million $166.34 Million --
pp = percentage points

About Quidel Corporation

NASDAQ:QDEL USA Medical Devices
Market Cap
$966.23 Million
Market Cap Rank
#9244 Global
#2608 in USA
Share Price
$14.09
Change (1 day)
+0.43%
52-Week Range
$9.96 - $35.38
All Time High
$301.96
About

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laborator… Read more